| 1 |
2024 |
Ishfaq Ahmad Ahanger, Tanveer Ali Dar. Small molecule modulators of alpha-synuclein aggregation and toxicity: Pioneering an emerging arsenal against Parkinson’s disease, Ageing Research Reviews. 2024; 101: 102538102538.
https://doi.org/10.1016/j.arr.2024.102538 |
| 2 |
2024 |
Anns Mahboob, Hasan Ali, AlJazi AlNaimi, Mahmoud Yousef, Mlaak Rob, Nawaf Ahmad Al-Muhannadi, Degiri Kalana Lasanga Senevirathne, Ali Chaari. Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy, Cells. 2024; 13: 1527.
https://doi.org/10.3390/cells13181527 |
| 3 |
2024 |
Emma Boström, Sagar S. Bachhav, Hao Xiong, Cindy Zadikoff, Qingbo Li, Eric Cohen, Ingeborg Dreher, Anna Torrång, Gunilla Osswald, Mikael Moge, Paulina Appelkvist, Johanna Fälting, Tomas Odergren. Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults, The Journal of Clinical Pharmacology. 2024; 64: 1432.
https://doi.org/10.1002/jcph.6103 |
| 4 |
2025 |
Ling-Xiao Yi, Eng King Tan, Zhi Dong Zhou. The α-Synuclein Seeding Amplification Assay for Parkinson’s Disease, International Journal of Molecular Sciences. 2025; 26: 389.
https://doi.org/10.3390/ijms26010389 |
| 5 |
2025 |
YuTing Liu, Minhua Yang, Kyle Fraser, Danielle Graham, Paul H. Weinreb, Andreas Weihofen, Warren D. Hirst, Jesse M. Cedarbaum, Blake Pepinsky. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples, The Journal of Pharmacology and Experimental Therapeutics. 2025; 392: 100003100003.
https://doi.org/10.1124/jpet.124.002199 |
| 6 |
2025 |
Jean-Christophe Rochet, Wenzhu Qi, Deniz Kirik. Zero-length crosslinking: A breakthrough approach for evaluating target engagement in α-synuclein immunotherapy, The Journal of Pharmacology and Experimental Therapeutics. 2025; 392: 100036100036.
https://doi.org/10.1016/j.jpet.2024.100036 |
